Cover Image
市場調查報告書

肌少症 : 開發平台分析

Sarcopenia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213093
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
肌少症 : 開發平台分析 Sarcopenia - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 60 Pages
簡介

所謂肌少症,定義為老齡化伴隨的肌力的量、功能低下。主要的症狀為,肥胖和步行、移動障礙,肌力不足,呼吸困難等。主要的治療方法,有藥物療法和荷爾蒙置換療法等。

本報告提供全球各國的肌少症治療用的開發中產品的開發情形相關分析、產品開發與上市的最新趨勢,及各臨床實驗階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等資訊、為您概述為以下內容。

目錄

簡介

  • 分析範圍

肌少症概要

治療藥的開發

  • 肌少症的開發中產品:概要
  • 肌少症的開發中產品:比較分析

各企業開發中的肌少症治療藥

大學/研究機關研究中的肌少症治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

肌少症治療藥:開發中的產品一覽(各企業)

肌少症治療藥:研究中的產品一覽(各大學/研究機關)

肌少症開發治療藥的企業

  • GlaxoSmithKline Plc
  • Myos Corporation
  • Neurotune AG
  • Novartis AG
  • PolyNovo Limited
  • PsiOxus Therapeutics Limited
  • Regeneron Pharmaceuticals, Inc.
  • 大日本住友製藥

肌少症:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • AOD-9604
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ARM-210
  • bimagrumab
  • BIO-101
  • BIO-103
  • Espindolol
  • NEP-28
  • NT-1654
  • 肌肉骨骼障礙用蛋白質
  • 肌少症的基因改造型蛋白質
  • S-107
  • 肌少症的、惡病質 Furin 抑制劑
  • 慢性風濕病、肌少症、惡病質用 JAK3 抑制劑
  • trevogrumab

肌少症治療藥:開發中產品的最新趨勢

肌少症治療藥:開發暫停的產品

肌少症治療藥:開發中止的產品

肌少症相關產品的開發的里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9569IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H2 2017, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

Sarcopenia is defined as the loss of mass and muscular function with age. Symptoms include obesity, difficulty walking or moving about, lack of strength and respiratory problems. Treatment includes medications and hormone replacement therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sarcopenia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sarcopenia - Overview
    • Sarcopenia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Sarcopenia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Sarcopenia - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Biophytis SAS
    • GlaxoSmithKline Plc
    • Immusoft Corp
    • MYOS RENS Technology Inc
    • Neurotune AG
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
    • Sumitomo Dainippon Pharma Co Ltd
    • Teijin Pharma Ltd
  • Sarcopenia - Drug Profiles
    • ARM-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATA-842 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVGN-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimagrumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Sarcopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Follistatin for Sarcopenia and Atherosclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEP-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-1654 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Proteins for Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Sarcopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TEISARM-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trevogrumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sarcopenia - Dormant Projects
  • Sarcopenia - Discontinued Products
  • Sarcopenia - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2017: BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia
      • May 03, 2017: BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial
      • Mar 27, 2017: Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study
      • Mar 21, 2017: BIOPHYTIS to present on BIO101 at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Barcelona
      • Mar 01, 2017: BIOPHYTIS: Full results of SARA-PK study confirm Sarconeos good pharmacokinetic profile in elderly patients
      • Dec 16, 2016: Biophytis presents preliminary clinical data of SARA - PK, and new preclinical data of Sarconeos for treating sarcopenia
      • Nov 29, 2016: BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile
      • Nov 22, 2016: BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients
      • Nov 15, 2016: BIOPHYTIS Presenting Four Posters on Sarconeos at 9th International Conference on Cachexia, Sarcopenia, and Muscle Wasting
      • Sep 22, 2016: BIOPHYTIS launches the second phase of Sarconeos pharmacokinetics study (SARA-PK) after successful completion of the initial phase
      • Aug 26, 2016: BIOPHYTIS: enrollment of the first subjects in the pharmacokinetics study on Sarcopenia
      • Jul 25, 2016: BIOPHYTIS Receives Belgian Regulatory Authorization to Start Sarconeos Pharmacokinetics Study in Elderly Healthy Volunteers (SARA-PK)
      • Apr 12, 2016: BIOPHYTIS to Present Key Research Findings on Company Lead Compound at Upcoming Scientific Conferences
      • Mar 11, 2016: BIOPHYTIS Receives positive Scientific Advice on SARCOB BIO101 Clinical Development Plan from Belgian Regulatory Authority
      • Nov 26, 2015: Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Sarcopenia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Sarcopenia - Pipeline by Amgen Inc, H2 2017
  • Sarcopenia - Pipeline by Biophytis SAS, H2 2017
  • Sarcopenia - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Sarcopenia - Pipeline by Immusoft Corp, H2 2017
  • Sarcopenia - Pipeline by MYOS RENS Technology Inc, H2 2017
  • Sarcopenia - Pipeline by Neurotune AG, H2 2017
  • Sarcopenia - Pipeline by Novartis AG, H2 2017
  • Sarcopenia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Sarcopenia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
  • Sarcopenia - Pipeline by Teijin Pharma Ltd, H2 2017
  • Sarcopenia - Dormant Projects, H2 2017
  • Sarcopenia - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Sarcopenia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top